MedTrace Logo

The Risk of Major Bleeding With Novel Anti-platelets: A Comparison of Ticagrelor With Clopidogrel in a Real World Population of 5000 Patients Treated for Acute Coronary Syndrome

NCT02484924 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 5225

Last updated 2022-06-09

No results posted yet for this study

Summary

A retrospective real world analysis of bleeding events with ticagrelor compared to clopidogrel in ACS patients.

Conditions

  • Acute Coronary Syndrome
  • Bleeding
  • Novel Anti-platelets
  • Ticagrelor
  • Clopidogrel

Interventions

DRUG

Ticagrelor

No intervention- purely observational

Sponsors & Collaborators

  • Liverpool Heart and Chest Hospital NHS Foundation Trust

    collaborator OTHER

  • Countess of Chester NHS Foundation Trust

    collaborator OTHER

  • St Helens & Knowsley Teaching Hospitals NHS Trust

    collaborator OTHER

  • Liverpool University Hospitals NHS Foundation Trust

    lead OTHER_GOV

Principal Investigators

  • Aleem Khand, MBChB MRCP · University Hospital Aintree

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-06-30
Primary Completion
2016-06-30
Completion
2016-06-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02484924 on ClinicalTrials.gov